Zoetis Inc. Class A

169.86+2.05+1.22%Vol 1.47M1Y Perf -17.00%
Feb 2nd, 2023 13:32 DELAYED
BID169.81 ASK169.88
Open167.27 Previous Close167.81
Pre-Market168.95 After-Market-
 1.14 0.68%  - -
Target Price
207.88 
Analyst Rating
Strong Buy 1.23
Potential %
21.97 
Finscreener Ranking
★★+     47.80
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★+     47.88
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     64.10
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★★     44.14
Price Range Ratio 52W %
56.33 
Earnings Rating
Sell
Market Cap79.17B 
Earnings Date
14th Feb 2023
Alpha0.01 Standard Deviation0.06
Beta0.73 

Today's Price Range

166.71170.62

52W Range

124.15205.31

5 Year PE Ratio Range

6.9018.20

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
-0.26%
1 Month
14.51%
3 Months
13.88%
6 Months
-6.16%
1 Year
-17.00%
3 Years
25.04%
5 Years
118.56%
10 Years
453.32%

TickerPriceChg.Chg.%
ZTS169.862.05001.22
AAPL149.984.54993.13
GOOG107.726.29006.20
MSFT262.389.63003.81
XOM111.07-3.6700-3.20
WFC47.400.37000.79
JNJ163.99-0.9300-0.56
FB196.640.99000.51
GE83.531.21001.47
JPM139.29-0.3000-0.21
 
ProfitabilityValueIndustryS&P 500US Markets
70.00
34.80
40.50
28.40
27.33
RevenueValueIndustryS&P 500US Markets
6.04B
12.96
8.93
8.86
DividendsValueIndustryS&P 500US Markets
1.02
1.50
21.19
21.64
Payout ratio22.00
Earnings HistoryEstimateReportedSurprise %
Q03 20221.241.21-2.42
Q02 20221.221.20-1.64
Q01 20221.221.328.20
Q04 20210.961.004.17
Q03 20211.101.2513.64
Q02 20211.081.1910.19
Q01 20211.041.2621.15
Q04 20200.860.915.81
Earnings Per EndEstimateRevision %Trend
12/2022 QR1.15-5.74Negative
12/2022 FY4.87-2.40Negative
3/2023 QR1.38-4.17Negative
12/2023 FY5.37-4.28Negative
Next Report Date14th Feb 2023
Estimated EPS Next Report1.14
Estimates Count8
EPS Growth Next 5 Years %10.80
Volume Overview
Volume1.47M
Shares Outstanding466.07K
Shares Float470.35M
Trades Count26.27K
Dollar Volume247.32M
Avg. Volume2.31M
Avg. Weekly Volume2.16M
Avg. Monthly Volume2.39M
Avg. Quarterly Volume2.38M

Zoetis Inc. Class A (NYSE: ZTS) stock closed at 167.81 per share at the end of the most recent trading day (a 1.4% change compared to the prior day closing price) with a volume of 2.88M shares and market capitalization of 79.17B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 11300 people. Zoetis Inc. Class A CEO is Kristin C. Peck.

The one-year performance of Zoetis Inc. Class A stock is -17%, while year-to-date (YTD) performance is 14.51%. ZTS stock has a five-year performance of 118.56%. Its 52-week range is between 124.1483 and 205.305, which gives ZTS stock a 52-week price range ratio of 56.33%

Zoetis Inc. Class A currently has a PE ratio of 8.40, a price-to-book (PB) ratio of 14.76, a price-to-sale (PS) ratio of 11.35, a price to cashflow ratio of 37.70, a PEG ratio of 2.32, a ROA of 16.35%, a ROC of 18.35% and a ROE of 47.92%. The company’s profit margin is 27.33%, its EBITDA margin is 40.50%, and its revenue ttm is $6.04 Billion , which makes it $12.96 revenue per share.

Of the last four earnings reports from Zoetis Inc. Class A, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $1.14 for the next earnings report. Zoetis Inc. Class A’s next earnings report date is 14th Feb 2023.

The consensus rating of Wall Street analysts for Zoetis Inc. Class A is Strong Buy (1.23), with a target price of $207.88, which is +21.97% compared to the current price. The earnings rating for Zoetis Inc. Class A stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Zoetis Inc. Class A has a dividend yield of 1.02% with a dividend per share of $1.50 and a payout ratio of 22.00%.

Zoetis Inc. Class A has a Buy technical analysis rating based on Technical Indicators (ADX : 8.70, ATR14 : 5.03, CCI20 : 88.49, Chaikin Money Flow : 0.24, MACD : 4.54, Money Flow Index : 76.58, ROC : 4.28, RSI : 67.74, STOCH (14,3) : 70.24, STOCH RSI : 0.48, UO : 64.86, Williams %R : -29.76), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Zoetis Inc. Class A in the last 12-months were: Abhay U. Nayak (Option Excercise at a value of $0), Glenn David (Option Excercise at a value of $2 515 017), Glenn David (Sold 32 390 shares of value $6 149 880 ), Gregory Norden (Option Excercise at a value of $0), Heidi C. Chen (Option Excercise at a value of $0), Kristin C. Peck (Option Excercise at a value of $672 106), Kristin C. Peck (Sold 20 000 shares of value $3 722 908 ), Linda Rhodes (Option Excercise at a value of $0), Louise M. Parent (Option Excercise at a value of $0), Michael B. McCallister (Option Excercise at a value of $0), Paul M. Bisaro (Option Excercise at a value of $0), Robert J. Polzer (Option Excercise at a value of $150 605), Robert J. Polzer (Sold 1 120 shares of value $192 383 ), Roman Trawicki (Option Excercise at a value of $525 060), Roman Trawicki (Sold 6 000 shares of value $1 128 900 ), Roxanne Lagano (Option Excercise at a value of $692 153), Roxanne Lagano (Sold 10 733 shares of value $1 942 735 ), Willie M. Reed (Option Excercise at a value of $0), Willie M. Reed (Sold 1 855 shares of value $301 085 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (81.82 %)
9 (81.82 %)
9 (81.82 %)
Moderate Buy
1 (9.09 %)
1 (9.09 %)
1 (9.09 %)
Hold
1 (9.09 %)
1 (9.09 %)
1 (9.09 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.23
Strong Buy
1.23
Strong Buy
1.23

Zoetis Inc. Class A

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

CEO: Kristin C. Peck

Telephone: +1 973 822-7000

Address: 10 Sylvan Way, Parsippany 07054, NJ, US

Number of employees: 11 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

58%42%

TipRanks News for ZTS

Sat, 10 Dec 2022 13:59 GMT Microsoft, Arista among stocks that can survive a triple whammy, Barrons says

- TipRanks. All rights reserved.

News

Stocktwits